| $381M | ||
| $350M | ||
| $215M | ||
| $107M | ||
| $100M | ||
| $91M |
Buys | $4,330,057 | 11 | 100 |
Sells | $0 | 0 | 0 |
| Kim Young-Jin | director | 1 | $4M | 0 | $0 | $4M |
| Evans Daron | CFO | 4 | $181,494 | 0 | $0 | $181,494 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer | 2 | $58,539 | 0 | $0 | $58,539 |
| Elam Nevan C | CEO | 1 | $50,880 | 0 | $0 | $50,880 |
| Karnawat Sunil Ratilal | Chief Commercial Officer | 1 | $19,599 | 0 | $0 | $19,599 |
| KREHER NERISSA | director | 1 | $9,997 | 0 | $0 | $9,997 |
| Hogenhuis Wladimir | director | 1 | $9,549 | 0 | $0 | $9,549 |
Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for metabolic conditions marked by persistent glucose imbalances, primarily serving the United States market. Its flagship product candidate, RZ358, a human monoclonal antibody, is currently progressing through Phase 2b clinical trials as a potential treatment for congenital hyperinsulinism, an exceptionally rare genetic disorder impacting pediatric patients. The company is also developing RZ402, a powerful and selective plasma kallikrein inhibitor, which is in Phase 1 clinical evaluation for the ongoing management of diabetic macular edema. Founded in 2010, the entity was formerly known as AntriaBio, Inc. before adopting the Rezolute, Inc. name in December 2017, and its operations are based out of Redwood City, California.
Over the last 12 months, insiders at Rezolute, Inc. have bought $4.33M and sold $0 worth of Rezolute, Inc. stock.
On average, over the past 5 years, insiders at Rezolute, Inc. have bought $5.58M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Kim Young-Jin (director) — $4M. Evans Daron (CFO) — $181,494. ROBERTS BRIAN KENNETH (Chief Medical Officer) — $58,539.
The last purchase of 10,000 shares for transaction amount of $28,500 was made by Evans Daron (CFO) on 2026‑03‑30.
| 2026-03-30 | Evans Daron | CFO | 10,000 0.0104% | $2.85 | $28,500 | +15.79% | ||
| 2025-12-16 | ROBERTS BRIAN KENNETH | Chief Medical Officer | 28,000 0.0254% | $1.70 | $47,600 | +58.91% | ||
| 2025-12-16 | Hogenhuis Wladimir | director | 5,650 0.0051% | $1.69 | $9,549 | +58.91% | ||
| 2025-12-15 | Elam Nevan C | CEO | 32,000 0.0338% | $1.59 | $50,880 | +96.93% | ||
| 2025-12-15 | Evans Daron | CFO | 45,000 0.0528% | $1.77 | $79,578 | +96.93% | ||
| 2025-12-15 | Karnawat Sunil Ratilal | Chief Commercial Officer | 12,100 0.013% | $1.62 | $19,599 | +96.93% | ||
| 2025-12-09 | Evans Daron | CFO | 10,549 0.0185% | $5.04 | $53,167 | -67.51% | ||
| 2025-06-25 | ROBERTS BRIAN KENNETH | Chief Medical Officer | 2,500 0.0029% | $4.38 | $10,939 | -5.54% | ||
| 2025-06-24 | Evans Daron | CFO | 5,000 0.0058% | $4.05 | $20,250 | -0.94% | ||
| 2025-06-13 | Kim Young-Jin | director | 1.23M 1.1136% | $3.25 | $4M | -1.90% | ||
| 2025-06-13 | KREHER NERISSA | director | 3,076 0.0028% | $3.25 | $9,997 | -1.90% | ||
| 2025-03-31 | Hogenhuis Wladimir | director | 6,758 0.0112% | $2.92 | $19,733 | +48.62% | ||
| 2025-03-27 | Elam Nevan C | CEO | 12,302 0.0198% | $2.85 | $34,999 | +47.60% | ||
| 2025-03-26 | Evans Daron | CFO | 20,000 0.0349% | $2.88 | $57,700 | +57.88% | ||
| 2025-02-18 | Hogenhuis Wladimir | director | 10,000 0.0168% | $4.70 | $47,000 | -8.80% | ||
| 2024-12-18 | Evans Daron | CFO | 10,000 0.0181% | $4.29 | $42,900 | +21.69% | ||
| 2024-12-12 | Evans Daron | CFO | 9,000 0.0155% | $4.60 | $41,400 | +7.00% | ||
| 2024-09-24 | Hogenhuis Wladimir | director | 4,259 0.0075% | $4.70 | $20,017 | +2.99% | ||
| 2024-06-25 | Kim Young-Jin | director | 1.25M 2.5143% | $4.00 | $5M | +16.93% | ||
| 2024-06-25 | Hogenhuis Wladimir | director | 4,815 0.01% | $4.15 | $19,982 | +16.93% |
| Kim Young-Jin | director | 8423386 8.7477% | $32.09M | 4 | 0 | +46.4% |
| Elam Nevan C | CEO | 641119 0.6658% | $2.44M | 3 | 0 | +114.05% |
| Evans Daron | CFO | 414462 0.4304% | $1.58M | 14 | 0 | +73.51% |
| ROBERTS BRIAN KENNETH | Chief Medical Officer | 308352 0.3202% | $1.17M | 13 | 0 | +86.08% |
| Hogenhuis Wladimir | director | 119675 0.1243% | $455,961.75 | 7 | 0 | <0.0001% |
| Karnawat Sunil Ratilal | Chief Commercial Officer | 71542 0.0743% | $272,575.02 | 1 | 0 | |
| KREHER NERISSA | director | 37576 0.039% | $143,164.56 | 1 | 0 | |
| Genexine Inc. | 10 percent owner | 91300933 94.8164% | $347.86M | 1 | 0 | |
| HANDOK, INC. | 5942617 6.1714% | $22.64M | 72 | 0 | <0.0001% | |
| Welch David F | director | 1811415 1.8812% | $6.9M | 13 | 0 | |
| CHU JUE MIN | 10 percent owner | 893750 0.9282% | $3.41M | 1 | 0 | |
| Labrucherie Gil M | director | 53572 0.0556% | $204,109.32 | 1 | 0 | <0.0001% |
| WOLKIN ORIT | 10 percent owner | 0 0% | $0 | 1 | 1 | |
| KAEYO INVESTMENTS LTD | 10 percent owner | 0 0% | $0 | 1 | 1 | |
| TURNOWSKI GUY | Secretary | 0 0% | $0 | 0 | 1 | |
| BAR NIR | President and Treasurer | 0 0% | $0 | 1 | 1 |
Rezolute, Inc. (RZLT) | $27,082,337 | 104 | 6.73% | $366.87M |
$6,125,624 | 95 | -6.06% | $324.54M | |
$1,323,997 | 34 | 0.21% | $445.01M | |
$22,017,898 | 24 | 39.19% | $353.78M | |
$2,516,932 | 19 | -15.78% | $402.84M | |
$112,238,340 | 19 | 39.16% | $414.11M | |
$15,467,825 | 18 | 4.98% | $362.62M | |
$133,809,976 | 13 | 31.29% | $450.36M | |
$65,355,913 | 13 | -3.42% | $392.9M | |
$57,263,116 | 11 | -8.37% | $434.09M | |
$176,565 | 8 | -2.61% | $354.72M | |
$17,675,244 | 7 | 92.20% | $357.31M | |
$12,035,408 | 5 | -37.54% | $398.06M | |
$58,352 | 4 | -43.78% | $383.7M | |
$51,688 | 4 | -26.18% | $351.81M | |
$184,294 | 3 | -10.64% | $351.32M | |
$2,720,023 | 3 | -11.76% | $442.61M | |
$10,104,842 | 3 | 5.45% | $324.29M | |
$20,020,000 | 1 | -75.24% | $335.44M |
| Increased Positions | 86 | +66.67% | 42M | +48.15% |
| Decreased Positions | 59 | -45.74% | 38M | -43.86% |
| New Positions | 40 | New | 14M | New |
| Sold Out Positions | 35 | Sold Out | 24M | Sold Out |
| Total Postitions | 156 | +20.93% | 91M | +4.29% |
| Federated Hermes, Inc. | $30,385.00 | 15.09% | 14.03M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $27,635.00 | 13.73% | 12.76M | -47,643 | -0.37% | 2025-09-30 |
| Blackrock, Inc. | $10,835.00 | 5.38% | 5M | +922,911 | +22.61% | 2025-09-30 |
| Siren, L.L.C. | $10,544.00 | 5.24% | 4.87M | +5M | New | 2025-09-30 |
| Vanguard Group Inc | $9,548.00 | 4.74% | 4.41M | +387,502 | +9.63% | 2025-09-30 |
| Blackstone Inc. | $6,547.00 | 3.25% | 3.02M | -536,390 | -15.07% | 2025-09-30 |
| Mangrove Partners Im, Llc | $6,240.00 | 3.1% | 2.88M | +584,660 | +25.45% | 2025-09-30 |
| Marshall Wace, Llp | $5,907.00 | 2.93% | 2.73M | -158,166 | -5.48% | 2025-09-30 |
| Ubs Group Ag | $5,837.00 | 2.9% | 2.7M | -341,190 | -11.23% | 2025-09-30 |
| Great Point Partners I Lp | $5,308.00 | 2.64% | 2.45M | -581,653 | -19.18% | 2025-09-30 |